trending Market Intelligence /marketintelligence/en/news-insights/trending/h755YVJ04e2Q25r2LysfYA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Lilly to offer lower-priced versions of 2 Humalog-branded insulin products

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Lilly to offer lower-priced versions of 2 Humalog-branded insulin products

Eli Lilly and Co. will offer lower-priced versions of two of its branded insulin products.

Versions of Humalog Mix75/25 KwikPen and Humalog Junior will be available by mid-April, at half the price of the branded products.

The lower-priced version of Humalog Mix75/25 will be called insulin lispro protamine and insulin lispro injectable suspension Mix75/25 KwikPen.

Meanwhile, the lower-priced version of Humalog Junior KwikPen will be known as insulin lispro injection junior KwikPen.

The cost-effective insulins, which are identical molecules to the branded products, will have a list price of $265.20 for one pack of five KwikPens, the Indianapolis-based pharmaceutical company said.

Eli Lilly said it will negotiate with wholesalers and payers to make the additional lower-priced insulins available.

The company, which launched its first low-priced insulin in May 2019, also said about 10% of Humalog users have transitioned to the less expensive version.

The high prices of insulin, a product essential for diabetes patients, have been the subject of a number of congressional hearings in the U.S.